Jose Lora's questions to Heron Therapeutics Inc (HRTX) leadership • Q3 2024
Question
Jose Lora of Jefferies inquired about the anticipated uptake curve for ZYNRELEF following the FDA approval of the Vial Access Needle (VAN) and the expected mix of new versus existing customers.
Answer
CEO Craig Collard explained that the VAN will launch by the first week of December. The rollout strategy involves starting with a few key accounts to ensure a smooth process, then targeting previous users who discontinued ZYNRELEF due to preparation difficulties, and finally engaging new accounts identified through the CrossLink partnership. Collard emphasized that the VAN addresses a significant, long-standing issue with preparation time and sterility, creating strong potential for adoption.